Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7336055 | 0.88 | CYP1A2 (0.77) | CYP1A2MAPTGAACA12CA1 | |
| SCHEMBL31185994 | 0.87 | CYP1A2 (0.70) | CYP1A2MAPTGAACA12CA1 | |
| SCHEMBL1478915 | 0.86 | CYP1A2 (1.00) | CYP1A2MAPTGAACA12CA1 | |
| SCHEMBL14935831 | 0.85 | CYP1A2 (0.72) | CYP1A2MAPTGAACA12CA1 | |
| SCHEMBL1698714 | 0.85 | CYP1A2 (0.72) | CYP1A2MAPTGAACA12CA1 | |
| SCHEMBL9993619 | 0.85 | CYP1A2 (0.72) | CYP1A2MAPTGAACA12CA1 | |
| SCHEMBL2108801 | 0.85 | CYP1A2 (0.72) | CYP1A2MAPTGAACA12CA1 | |
| SCHEMBL127153 | 0.85 | CYP1A2 (0.72) | CYP1A2MAPTGAACA12CA1 | |
| SCHEMBL21371248 | 0.84 | CYP1A2 (0.70) | CYP1A2MAPTGAACA12CA1 | |
| Hydrochloric Acid SCHEMBL31098480 | 0.84 | CYP1A2 (0.70) | CYP1A2MAPTGAACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085057-A1 | SUBSTITUTED INDAZOLES USEFUL FOR TREATMENT AND PREVENTION OF ALLERGIC AND/OR INFLAMMATORY DISEASES IN ANIMALS | Bayer Pharma AG (DE) | 2026-03-26 | — | — | US | disclosed |
| US-12559473-B2 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2026-02-24 | — | — | US | disclosed |
| US-12459916-B2 | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-11-04 | — | — | US | disclosed |
| EP-4618984-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF PAIN AND INFLAMMATION | Elanco Animal Health GmbH (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-20250034111-A1 | SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-01-30 | — | — | US | disclosed |
| EP-3674298-B9 | SUBSTITUTED INDAZOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS | Bayer Pharma AG (DE) | 2024-06-19 | — | — | EP | disclosed |
| US-12006303-B2 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-06-11 | — | — | US | disclosed |
| US-12006304-B2 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-06-11 | — | — | US | disclosed |
| US-11992481-B2 | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-05-28 | — | — | US | disclosed |
| WO-2024108010-A1 | METHODS AND COMPOSITIONS FOR CONTROL OF PAIN AND INFLAMMATION | BAYER ANIMAL HEALTH GMBH (DE) | 2024-05-23 | — | — | WO | disclosed |
| EP-1646608-A1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL Pharmaceutical Co., Ltd. (KR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1591446-A1 | THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004113281-A1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2004-12-29 | — | — | WO | disclosed |
| EP-0930298-B1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2002-12-18 | — | — | EP | disclosed |
| CN-1344270-A | Functionalized heterocycles as chemokine receptor modulators | THOUSAND YEARS MEDICAMENTS INC (US) | 2002-04-10 | — | — | CN | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034111-A1 | SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS | CYP11B2, CYP11B1, CYP19A1 | CYP1A2 78/4885MAPT 1069/4885GAA 2628/4885 |
| US-12459916-B2 | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | AADAC, IDO1, HRH4 | CYP1A2 95/4885MAPT 1294/4885GAA 3641/4885 |
| US-20260085057-A1 | SUBSTITUTED INDAZOLES USEFUL FOR TREATMENT AND PREVENTION OF ALLERGIC AND/OR INFLAMMATORY DISEASES IN ANIMALS | HRH4, BRCA1, HRH1 | CYP1A2 211/4885MAPT 3835/4885GAA 4837/4885 |
| US-12559473-B2 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | CPT1A, CYP11B1, CYP11B2 | CYP1A2 151/4885MAPT 3599/4885GAA 4381/4885 |
| US-12006303-B2 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs | CYP11B2, CYP11B1, CYP19A1 | CYP1A2 67/4885MAPT 1157/4885GAA 2470/4885 |
| US-12006304-B2 | Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs | CYP11B2, CYP11B1, CYP19A1 | CYP1A2 67/4885MAPT 1157/4885GAA 2470/4885 |
| US-11992481-B2 | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | IDO2, IL33, IDO1 | CYP1A2 44/4885MAPT 1611/4885GAA 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.